Adjuvant chemotherapy in early-stage breast cancer: What, When, and for Whom?

Surgical Oncology Clinics of North America

Volumn 19, Issue 3, 2010, Pages 649-668

  Kelly, Catherine M ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Anthracyclines; Early stage breast cancer; Taxanes

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; EPOTHILONE DERIVATIVE; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OPTIMAL DRUG DOSE; PREDICTION; PROGNOSIS; RECURRENCE RISK; REVIEW; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS;

EID: 77954159226     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.03.007     Document Type: Review

References (99)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Berry D.A., Inoue L., Shen Y., et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006, 36:30-36.
3. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the breast health global initiative global summit 2007. Cancer 2008, 113:2221-2243.
4. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988, 48:7067-7071.
5. Bonadonna G., Brusamolino E., Valagussa P., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976, 294:405-410.
6. Fisher B., Redmond C., Dimitrov N.V., et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989, 320:473-478.
7. Mansour E.G., Gray R., Shatila A.H., et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J Clin Oncol 1998, 16:3486-3492.
8. Fisher B., Jeong J.H., Dignam J., et al. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001, 30:32-36.
9. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997, 89:1673-1682.
10. National Institutes of Health Consensus Development Panel. Adjuvant therapy for breast cancer. NIH Consensus Statement 2000, 17:1-35.
11. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
12. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942.
13. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol 2006, 17(Suppl 10):59-62.
14. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
15. Clarke M., Coates A.S., Darby S.C., et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008, 371:29-40.
16. Edge S.B., Compton D.R., April C.C., et al. AJCC Cancer Staging Manual 2009, Springer, New York. 7th edition.
17. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
18. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.I. 2010 Available at:, Accessed January 19, 2010. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
19. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
20. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19:980-991.
21. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005, 23:2716-2725.
22. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
23. Dowsett M, Cuzick, J, Wales, C et al. Risk of recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Presented at the 31st San Antonio Breast Cancer Symposium. San Antonio (TX), December 10-14, 2008.
24. Albain K., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
25. Mamounas E., Tang G., Fisher B., et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28(10):1677-1683.
26. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23:7265-7277.
27. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
28. Cuzick J., Dowsett M., Wale C., et al. Prognostic value of a combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score -Results from TransATAC [abstract 74]. Cancer Res 2009, 69(Suppl).
29. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
30. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192.
31. Cardoso F., Van't Veer L., Rutgers E., et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
32. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel every 3 weeks. J Clin Oncol 2005, 23(25):5983-5992.
33. Fisher B., Brown A.M., Dimitrov N.V., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990, 8:1483-1496.
34. Fisher B., Anderson S., Tan-Chiu E., et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001, 19:931-942.
35. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
36. Trudeau M., Charbonneau F., Gelmon K., et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005, 6:886-898.
37. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001, 19:37-43.
38. Jones L.W., Haykowsky M.J., Swartz J.J., et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007, 50:1435-1441.
39. Dressler L.G., Berry D.A., Broadwater G., et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005, 23:4287-4297.
40. Muss H.B., Thor A.D., Berry D.A., et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266.
41. Paik S., Bryant J., Park C., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90:1361-1370.
42. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006, 354:2103-2111.
43. Dhesy-Thind B., Pritchard K.I., Messersmith H., et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008, 109:209-229.
44. Jarvinen T.A., Liu E.T. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003, 78:299-311.
45. Beser A.R., Tuzlali S., Guzey D., et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 2007, 13:180-185.
46. Slamon D.J., Press M.F. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 2009, 101:615-618.
47. Slamon D, Eiermann W, Robert N, et al. BCIRG 006 Phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. Presented at San Antonio Annual Breast Cancer symposium. San Antonio (TX), December 10-13, 2009.
48. Esteva F.J., Hortobagyi G.N. Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009, 27:3416-3417.
49. Pritchard K.I. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?. J Clin Oncol 2009, 27:3875-3876.
50. Bria E., Nistico C., Cuppone F., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106:2337-2344.
51. Ferguson T., Wilcken N., Vagg R., et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007, 4. CD004421.
52. De Laurentiis M., Cancello G., D'Agostino D., et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26:44-53.
53. Mamounas E.P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696.
54. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027.
55. Roche H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24:5664-5671.
56. Martin M., Rodriguez-Lescure A., Ruiz A., et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100:805-814.
57. Ellis P., Barrett-Lee P., Johnson L., et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009, 373:1681-1692.
58. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
59. Goldstein L.O., Sparano A. J. E2197:Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005, 23(16S):A512.
60. Jones F., Shaughnessy J. Extended follow-up and analysis by age of the U.S Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007, 106(S1):A12.
61. ClinicalTrials.gov Available at:, Accessed January 25, 2010. http://clinicaltrials.gov/ct2/home.
62. Swain S.M., Jeong J.H., Geyer C.E., et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium. San Antonio (TX), December 10-14 2008.
63. Eiermann W., Pienkowski T., Crown J., et al. BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium. San Antonio (TX), December 10-14 2008.
64. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506.
65. Szakacs G., Paterson J.K., Ludwig J.A., et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
66. Giannakakou P., Sackett D.L., Kang Y.K., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272:17118-17125.
67. Kamath K., Wilson L., Cabral F., et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005, 280:12902-12907.
68. Rouzier R., Rajan R., Wagner P., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005, 102:8315-8320.
69. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.
70. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001, 6(Suppl 3):30-35.
71. Venturini M., Del Mastro L., Aitini E., et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005, 97:1724-1733.
72. Bonadonna G., Zambetti M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995, 273:542-547.
73. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
74. Hess K.R., Pusztai L., Buzdar A.U., et al. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003, 78:105-118.
75. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
76. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123:236-240.
77. Fisher B., Jeong J.H., Bryant J., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004, 364:858-868.
78. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
79. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
80. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
81. Buzdar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
82. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
83. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
84. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
85. Spielmann M., Roche H., Delozier T., et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
86. Perez E., Suman V.J., Davidson N.E., et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial [abstract 556]. J Clin Oncol 2005, 23:17s.
87. Gonzalez-Angulo A.M., Litton J.K., Broglio K.R., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009, 27:5700-5706.
88. Curigliano G., Viale G., Bagnardi V., et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699.
89. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393-10398.
90. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
91. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
92. Foulkes W.D., Brunet J.S., Stefansson I.M., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004, 64:830-835.
93. Foulkes W.D., Stefansson I.M., Chappuis P.O., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
94. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
95. O'Shaughnessy J.O., Pippen C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple negative breast cancer (TNBC): Results of a randomized phase II trial [abstract 3]. J Clin Oncol 2009, 27:18s. (Suppl).
96. Lohrisch C., Paltiel C., Gelmon K., et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006, 24:4888-4894.
97. Green M.C., Esteva F.J., Hortobagyi G.N. Neoadjuvant chemotherapy. Breast Dis 2009, 21:23-31.
98. Mieog J.S., van der Hage J.A., van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007, 94:1189-1200.
99. Hortobagyi G.N., Ames F.C., Buzdar A.U., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988, 62:2507-2516.